In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

In a pooled analysis of three randomized trials, CPAP had overall null cardiovascular effects in patients with obstructive ...

Eli Lilly said the highest dose of its daily obesity pill helped patients lose more than 12% of their body weight, or roughly ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to an average ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

Eli Lilly and Company (NYSE:LLY) will release earnings results for the second quarter before the opening bell on Thursday, ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.

A trial of Eli Lilly’s diabetes drug Mounjaro did not meet expectations for outperforming Trulicity in preventing heart ...

U.S. stock futures rose on Thursday after ending higher on Wednesday. Futures of major benchmark indices were up.